Primary cultures of rat type II alveolar epithelial cells (AECs) or human AEC-derived A549 cells, when exposed to bleomycin (BLEO), exhibited concentration-dependent apoptosis detected by altered nuclear morphology, fragmentation of DNA, activation of Caspase 3 and net cell loss over time. In both cell culture models, exposure to BLEO caused time-dependent increases in angiotensinogen (ANGEN) mRNA. Antisense oligonucleotides against ANGEN mRNA inhibited BLEO-induced apoptosis of rat AEC or A549 cells by 83% and 84%, respectively (p<0.01 and p<0.05) and prevented BLEOinduced net cell loss. Apoptosis of rat AECs or A549 cells in response to BLEO was inhibited 91% by the ACE inhibitor captopril or by 82%, respectively, by neutralizing antibodies specific for ANGII (both p<0.01). Antagonists of ANG receptor AT1 (losartan, L158809 or saralasin), but not an AT2-selective blocker (PD123319), inhibited BLEO-induced apoptosis of either rat AECs (79%, p<0.01) or A549 cells (83%, p<0.01) and also reduced the activity of Caspase 3 by 52% (p<0.05). These data indicate that BLEO, like FasL or TNF-α, induces transactivation of ANG synthesis de novo that is required for AEC apoptosis. They also support the theory that ANG system antagonists have potential for the blockade of AEC apoptosis in situ.
INTRODUCTION
Alveolar epithelial cells (AECs) have many important roles that are critical to normal lung function (14) . The death of AECs by apoptosis is now believed to be an important event in the pathogenesis of lung fibrosis (9) and in more acute lung injury (15, 24) . A variety of investigations have implicated important roles for key molecules such as tumor necrosis factor alpha (TNF-α) and Fas ligand (Fas L ), both known inducers of apoptosis in a variety of cell types, in the events that lead to fibrogenesis in the lung (6, 7, 16) .
In earlier work (28, 31) we showed that exposure of either primary cultures of rat AECs or the human AEC-derived A549 cell line to Fas L or TNF-α increases angiotensinogen (ANGEN) mRNA and protein, and evokes its subsequent conversion to angiotensin II (ANGII). Moreover, we found that transactivation of the ANGEN gene is required for AEC apoptosis in response to TNF-α or Fas ligand. Thus, AEC death in response to these could agents could be blocked by ANG receptor antagonists or inhibitors of ANG converting enzyme (ACEis), at least in vitro. Studies of another inducer of AEC apoptosis, the antiarrhythmic agent amiodarone, also showed that antagonists of ANG production or receptor interaction could prevent apoptosis of AECs in response to this benzofuran compound (1) .
For these reasons we hypothesized that AEC apoptosis in response to bleomycin (BLEO) might also require ANG synthesis and might therefore be inhibitable by ANG system antagonists. We report here that bleomycin, if applied to rat or human AECs in vitro, induces the expression of angiotensinogen mRNA and subsequent apoptosis that DNA or western blotting were from sources described earlier (29) . All other materials were of reagent grade and were obtained from Sigma Chemical Co., Saint Louis, MO.
MATERIALS AND METHODS

Reagents and materials:
Cell culture:
The human lung adenocarcinoma cell line A549 was obtained from the American Type Cell Culture Collection and cultured in Ham's F12 medium supplemented with 10% fetal bovine serum (FBS). Primary alveolar epithelial cells isolated from adult male Wistar rats as described earlier (31) . The primary cells were studied at day two of culture, a time at which they are type II cell-like by accepted morphologic and biochemical criteria (17) . Primary cell preparations were of better than 90% purity assessed by acridine orange staining as described previously (28, 31) . All cells were grown in 24-or 6-well chambers and were analyzed at subconfluent densities of 80-90%. All subsequent incubations with BLEO and/or other test agents were performed in 6 serum-free medium. The cells were exposed to caspase inhibitors or antagonists of the angiotensin system 30 minutes before exposure to BLEO for 1-20 hours as indicated.
Quantitation of apoptosis and cell loss: Detection of apoptotic cells with propidium iodide (PI) was conducted as described earlier (28, 31) following digestion of ethanol-fixed cells with DNase-free RNase in PBS containing 5ug/ml PI. In these assays, For RTPCR of rat-specific gene products, the following primers were used: for angiotensinogen, coding = 5'-CCTCGCTCTCTGGACTTATC-3', and uncoding = 5'-CAGACACTGAGGTGCTGTTG-3', which yields a PCR product of 226bp by singlestep RTPCR (20) . For β-microglobulin, the primers used were: coding = 5' -CTCCCCAAA-TTCAAGTGTACTCTCG-3', and uncoding = 5'-GAGTGACGTGTTTAACTCTGCA-AGC-3', which yields a product of 249bp (11) . For RT-PCR from human A549 cells, the following primers were used: for angiotensinogen, coding = 5'GCTTTC-AACACCTACGTCCA3', and uncoding = 5'AGCTGTTGGGTAGACTCTGT3'. These primers yield a final PCR product of 509bp 
RESULTS
Exposure of primary cultures of rat AECs or A549 cells to BLEO for 20 hours caused apoptosis detectable by nuclear fragmentation, DNA fragmentation and by immunolabeling of the active form of Caspase 3 ( Figure 1 ). Although these markers were detected in a minor fraction of the cells, the apoptosis induced was sufficient to reduce the total cell number significantly over time (see Figure 1D -F and quantitation in Figure   7B ). Scoring of fragmented nuclei revealed dose-dependent apoptosis that reached statistical significance beginning at 0.5mU/ml in primary AECs ( Figure 2 ) and at 1mU/ml in A549 cells (not shown). The nuclear fragmentation was blocked by the broadspectrum caspase inhibitor ZVAD-fmk (60uM) or by the endonuclease inhibitor aurintricarboxylic acid (ATA, 10uM), confirming the specificity of the assay for apoptosis. Apoptosis of the rat AECs also was blocked by the ACE inhibitor captopril (CAPTO, 500ng/ml) and by the nonselective ANG receptor antagonist saralasin (SARAL, 50ug/ml), in agreement with earlier studies of Fas-and TNF-induced AEC apoptosis (28, 31) . 
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DISCUSSION
The results described here agree with previous studies from this laboratory that showed a requirement for autocrine ANGII production and receptor interaction for AEC apoptosis in response to Fas L or TNF-α (28,31). Other authors also have reported DNA damage and death of AECs in response to bleomycin (7, 10) . Although a previous report of bleomycin action on A549 cells described no influence of the drug on cell viability in vitro (22) , the levels of apoptosis described here (apoptotic index about 10-20%, see
Figures 1 and 2) suggest that cell death at the relatively low doses used in that study (0.1-2mU/ml) may have gone undetected. Nonetheless, the levels of apoptosis reported here are more than sufficient to result in significant net cell loss in a relatively short period of time (see Figure 7 ). More importantly, both the cell loss and markers of apoptosis could be blocked by ANG system antagonists, consistent with the theory that these agents can prevent apoptosis, and thus cell loss, in response to bleomycin.
The findings that bleomycin-induced apoptosis of AECs could be blocked by the AT1-selective antagonists losartan ( Figure 3 ) and L158809 ( Figure 4) but not by the AT2-selective antagonist PD123319 are in agreement with our recent demonstration that the AT1 receptor subtype mediates AEC apoptosis in response to purified ANGII (18) .
They also support the contention that autocrine production of ANGII and binding to its receptor(s) are required for the apoptotic response. This contention also is supported by the ability of ANGEN antisense oligonucleotides or a neutralizing antibody that recognizes ANGII, but not ANGI or ANGEN, to essentially abrogate apoptosis and prevent net cell loss in response to bleomycin (Figures 4 and 7) .
In an earlier report we described the induction of apoptosis in AECs by exposure to purified ANGII (32) , which also occurred in a concentration-dependent manner with an EC 50 of 10nM and 50nM, respectively, for primary AECs and A549 cells, to BLEO (25mU/ml) for the indicated times and total RNA was isolated. RTPCR was performed as described before (28, 31) with primers specific for rat or human angiotensinogen (ANGEN), β-microglobulin (β-MG) or β-actin as control mRNAs. 
